BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 31711919)

  • 1. FAM122A supports the growth of hepatocellular carcinoma cells and its deletion enhances Doxorubicin-induced cytotoxicity.
    Zhou Y; Shi WY; He W; Yan ZW; Liu MH; Chen J; Yang YS; Wang YQ; Chen GQ; Huang Y
    Exp Cell Res; 2020 Feb; 387(1):111714. PubMed ID: 31711919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FAM122A maintains DNA stability possibly through the regulation of topoisomerase IIα expression.
    Wang YQ; Yang YS; Chen J; Liu MH; Chen GQ; Huang Y
    Exp Cell Res; 2020 Nov; 396(1):112242. PubMed ID: 32866497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MiR-26 enhances chemosensitivity and promotes apoptosis of hepatocellular carcinoma cells through inhibiting autophagy.
    Jin F; Wang Y; Li M; Zhu Y; Liang H; Wang C; Wang F; Zhang CY; Zen K; Li L
    Cell Death Dis; 2017 Jan; 8(1):e2540. PubMed ID: 28079894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Knockdown of eukaryotic translation initiation factor 5A2 enhances the therapeutic efficiency of doxorubicin in hepatocellular carcinoma cells by triggering lethal autophagy.
    Tang Y; Chen K; Luan X; Zhang J; Liu R; Zheng X; Xie S; Ke H; Zhang X; Chen W
    Int J Oncol; 2020 Dec; 57(6):1368-1380. PubMed ID: 33174013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protein phosphatase 2A-B55δ enhances chemotherapy sensitivity of human hepatocellular carcinoma under the regulation of microRNA-133b.
    Zhuang Q; Zhou T; He C; Zhang S; Qiu Y; Luo B; Zhao R; Liu H; Lin Y; Lin Z
    J Exp Clin Cancer Res; 2016 Apr; 35():67. PubMed ID: 27074866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. WM130 preferentially inhibits hepatic cancer stem-like cells by suppressing AKT/GSK3β/β-catenin signaling pathway.
    Ni CX; Qi Y; Zhang J; Liu Y; Xu WH; Xu J; Hu HG; Wu QY; Wang Y; Zhang JP
    Oncotarget; 2016 Nov; 7(48):79544-79556. PubMed ID: 27783993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MiR-101 and doxorubicin codelivered by liposomes suppressing malignant properties of hepatocellular carcinoma.
    Xu F; Liao JZ; Xiang GY; Zhao PX; Ye F; Zhao Q; He XX
    Cancer Med; 2017 Mar; 6(3):651-661. PubMed ID: 28135055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modified AS1411 Aptamer Suppresses Hepatocellular Carcinoma by Up-Regulating Galectin-14.
    Cho Y; Lee YB; Lee JH; Lee DH; Cho EJ; Yu SJ; Kim YJ; Kim JI; Im JH; Lee JH; Oh EJ; Yoon JH
    PLoS One; 2016; 11(8):e0160822. PubMed ID: 27494117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces Growth of Hepatocellular Carcinoma Cells In Vitro and in Mice by Inhibiting Cell Division Cycle 37 Signaling.
    Chen B; Wei W; Ma L; Yang B; Gill RM; Chua MS; Butte AJ; So S
    Gastroenterology; 2017 Jun; 152(8):2022-2036. PubMed ID: 28284560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. miR-223 overexpression inhibits doxorubicin-induced autophagy by targeting FOXO3a and reverses chemoresistance in hepatocellular carcinoma cells.
    Zhou Y; Chen E; Tang Y; Mao J; Shen J; Zheng X; Xie S; Zhang S; Wu Y; Liu H; Zhi X; Ma T; Ni H; Chen J; Chai K; Chen W
    Cell Death Dis; 2019 Nov; 10(11):843. PubMed ID: 31695022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Downregulation of Peptidylprolyl isomerase A promotes cell death and enhances doxorubicin-induced apoptosis in hepatocellular carcinoma.
    Cheng S; Luo M; Ding C; Peng C; Lv Z; Tong R; Xiao H; Xie H; Zhou L; Wu J; Zheng S
    Gene; 2016 Oct; 591(1):236-244. PubMed ID: 27397650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. miR-505 enhances doxorubicin-induced cytotoxicity in hepatocellular carcinoma through repressing the Akt pathway by directly targeting HMGB1.
    Lu L; Zhang D; Xu Y; Bai G; Lv Y; Liang J
    Biomed Pharmacother; 2018 Aug; 104():613-621. PubMed ID: 29803174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FAM122A, a new endogenous inhibitor of protein phosphatase 2A.
    Fan L; Liu MH; Guo M; Hu CX; Yan ZW; Chen J; Chen GQ; Huang Y
    Oncotarget; 2016 Sep; 7(39):63887-63900. PubMed ID: 27588481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma.
    Karkampouna S; van der Helm D; Gray PC; Chen L; Klima I; Grosjean J; Burgmans MC; Farina-Sarasqueta A; Snaar-Jagalska EB; Stroka DM; Terracciano L; van Hoek B; Schaapherder AF; Osanto S; Thalmann GN; Verspaget HW; Coenraad MJ; Kruithof-de Julio M
    J Pathol; 2018 Jul; 245(3):297-310. PubMed ID: 29604056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DEPDC1 promotes cell proliferation and suppresses sensitivity to chemotherapy in human hepatocellular carcinoma.
    Zhou C; Wang P; Tu M; Huang Y; Xiong F; Wu Y
    Biosci Rep; 2019 Jul; 39(7):. PubMed ID: 31189746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Upregulation of the oncoprotein SET determines poor clinical outcomes in hepatocellular carcinoma and shows therapeutic potential.
    Hung MH; Chen YL; Chu PY; Shih CT; Yu HC; Tai WT; Shiau CW; Chen KF
    Oncogene; 2016 Sep; 35(37):4891-902. PubMed ID: 26876205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MicroRNA-6809-5p mediates luteolin-induced anticancer effects against hepatoma by targeting flotillin 1.
    Yang PW; Lu ZY; Pan Q; Chen TT; Feng XJ; Wang SM; Pan YC; Zhu MH; Zhang SH
    Phytomedicine; 2019 Apr; 57():18-29. PubMed ID: 30668319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of mTORC2 Induces Cell-Cycle Arrest and Enhances the Cytotoxicity of Doxorubicin by Suppressing MDR1 Expression in HCC Cells.
    Chen BW; Chen W; Liang H; Liu H; Liang C; Zhi X; Hu LQ; Yu XZ; Wei T; Ma T; Xue F; Zheng L; Zhao B; Feng XH; Bai XL; Liang TB
    Mol Cancer Ther; 2015 Aug; 14(8):1805-15. PubMed ID: 26026051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. linc‑ROR facilitates hepatocellular carcinoma resistance to doxorubicin by regulating TWIST1‑mediated epithelial‑mesenchymal transition.
    Zhang Y; Wu W; Sun Q; Ye L; Zhou D; Wang W
    Mol Med Rep; 2021 May; 23(5):. PubMed ID: 33760121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of miR-1258 contributes to carcinogenesis and progression of liver cancer through targeting CDC28 protein kinase regulatory subunit 1B.
    Hu M; Wang M; Lu H; Wang X; Fang X; Wang J; Ma C; Chen X; Xia H
    Oncotarget; 2016 Jul; 7(28):43419-43431. PubMed ID: 27270326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.